The invoX Respiratory Innovation Centre is dedicated to the development of innovative and generic drug-device combination products which use the Softhaler®, a next-generation soft-mist device, to deliver known active pharmaceutical ingredients (APIs), new chemical entities (NCEs) and biomolecules to the lung.
Our respiratory team has developed a next-generation, proprietary soft-mist inhalation platform device, the Softhaler®, which uses differentiated technology to deliver propellant-free liquid-based formulations to the lung.
Our technology has a greener footprint than traditional inhalers due to simpler, typically water-based formulations which require a less intensive manufacturing process and contain no propellants or other volatile chemicals of environmental concern.
The respiratory team is made up of a multicultural international group of highly experienced individuals with backgrounds in respiratory and device technology. All our team members have a mutual passion for developing and bringing to the market new respiratory products that can help improve the lives of patients.